摘要
目的评价华蟾素经静脉、肝动脉序贯给药治疗原发性肝癌的临床疗效。方法将69例原发性肝癌患者随机分为治疗组、对照1组及对照2组各23例,治疗组予经肝动脉灌注华蟾素联合介入栓塞治疗,前后各静滴华蟾素注射液14d;对照1组经肝动脉灌注华蟾素联合介入栓塞治疗;对照2组经肝动脉灌注5-Fu、DDP、TH P-ADM联合介入栓塞。观察各组近期疗效、生存率、生活质量、甲胎蛋白(AFP)变化及T细胞亚群和NK细胞比例。结果治疗组、对照1组、对照2组近期疗效有效率分别为78.26%、47.83%、43.48%,治疗组明显高于对照组;治疗组半年、1年、2年生存率与对照1、2组比较差异无统计学意义;治疗组、对照1组、对照2组治疗后AFP下降率分别为69.57%、39.13%、34.78%,治疗组亦高于对照组;治疗组、对照1组、对照2组生活质量稳定改善率分别为86.96%、78.26%、43.48%,治疗组及对照1组均高于对照2组;治疗后治疗组CD3+、CD4+、NK比例均较两对照组高。结论华蟾素经静脉、肝动脉序贯给药联合介入栓塞治疗原发性肝癌近期疗效优于单纯华蟾素经肝动脉灌注栓塞及经导管肝动脉化疗栓塞(TACE)治疗,并能改善患者生活质量,提高免疫功能。
Objective： To evaluate the effect of sequential therapy of cinobufotalin intravenous and transcatheter arterial infusion in the treatment of primary liver cancer. Methods： 69 patients with primary liver cancer were divided into treatment group, the l st control group and the 2nd control group. Patients in treatment group were administrated cinobufotalin via venous before and after cinobufotalin infuse via arterial and transcatheter arterial embolization for 14 d. Patients in the 1st group were administrated cinobufotalin infuse via arterial and transcatheter arterial embolization. Patients in the 2nd control group were given transcatheter arterial chemoembolazition （TACE） therapy. The recent effect, survival ratio, the change of life quality and AFP, the subgroup of T cells and ratio of NK cells were observed. Results： The recent effect rates were 78.26%, 47.83% and 43.48% in the treatment, the 1st and 2nd control group respectively, with significant difference between the treatment and control groups. There were no significant differences of half year, one year and two year survival ratio between the treatment and control groups. The ratio of AFP decrease were 69.57% ,39. 13% and 34.78% after therapy in the treatment, the 1st and 2nd control group respectively, with significant difference between the treatment and control groups. The ratio of stability and improvement of life quality were 86.96%, 78.26% and 43.48% in the treatment, the 1st and 2nd control group respectively, the treatment and 1st control group were better than the 2nd control group. There were significant difference between them. The ratio of CD3^＋, CD4^＋, NK were significant higher in treatment group. Conclusion： The near time effect rate on treatment of primary liver cancer of sequential therapy of einobufotalin intravenous and transcathether arterial infusion and embolization were better than the cinobufotalin transcathether arterial infusion and TACE. It can also improve the quality of life and immune function.
出处
《中国中医急症》
2009年第4期525-527,共3页
Journal of Emergency in Traditional Chinese Medicine
关键词
原发性肝癌
华蟾素
序贯治疗
经导管肝动脉化疗栓塞
Primary liver cancer
Cinobufotalin
Sequential therapy
Transcather arterial ehemoembolization
